trial summary · NCT06995521
Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population
Use of Vorinostat as GVHD Prophylaxis in Children, Adolescents, and Young Adults With Non-Malignant Disorders Undergoing Allogeneic Blood and Marrow Transplantation
Trial record from the TrialBase DB dataset, status RECRUITING, condition GVHD, sponsored by Sung Won Choi. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This is a single-arm, open label, phase 2 study to determine the safety and efficacy of vorinostat without serotherapy as GVHD prophylaxis when combined with either tacrolimus and methotrexate or post-transplant cyclophosphamide, tacrolimus, and mycophenolate in patients aged 1 to 26 years of age with non-malignant disorders undergoing bone marrow transplant following myeloablative conditioning.
Source record: https://clinicaltrials.gov/study/NCT06995521
Facts
| registry id | NCT06995521 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | GVHD |
| sponsor | Sung Won Choi |
| sponsor class | OTHER |
| enrollment | 55 |
| start date | 2026-12 |
| primary completion | 2028-09 |
| completion | 2028-09 |
| results posted | not reported |
Conditions
- GVHD
Interventions
- Vorinostat
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.